Synthekine presented data at SITC on its α/β-IL-2 receptor biased partial agonist showing a 53% response rate in PD-L1 negative nonsquamous NSCLC
Nov 8, 2025
1 min read
Co-Founder & CEO Debanjan Ray walks us through learnigs the IL-2 space has seen over the years, and describes why Synthekine is targeting both the α and β receptors in this case. In addition to the phase 1a/1b that is reading at SITC, Synthekine has already started a randomized phase 2 study.
.png){kind=logo}